Base Therapeutics

Focus: Base Therapeutics is a gene-edited cell therapy company focused on oncology and immunology applications, operating from Shanghai with an early-stage pipeline in clinical development.

Oncology Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Base Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Base Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

NK520

Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Clinical Trials (2)

NCT06541405Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Help build intelligence for Base Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in gene-edited cell therapies, an emerging modality with significant clinical validation potential
Focus on high-unmet-need oncology indications (osteosarcoma, relapsed/refractory AML) with commercial tailwinds
China-based platform provides geographic arbitrage and access to large patient populations for rare disease development

Watch Out For

No active job openings and minimal public visibility suggest limited near-term hiring or company growth momentum
Pipeline consists exclusively of Phase 1 programs with no Phase 2/3 progression, indicating early-stage risk and uncertain clinical proof-of-concept

Generated by Claude from Base Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT06541444Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

NK510

Osteosarcoma

Phase 1

Clinical Trials (5)

NCT06097962Safety and Efficacy of NK510 to Treat NSCLC

Phase 1

NCT07166263Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer

Phase 1

NCT06117878Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

Phase 1

+2 more

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 7 clinical trials

Top TAs: Oncology, Immunology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

6 pipeline

Immunology

1 pipeline

Marketed

Pipeline